Moxie Dwight
Officer at Revance Therapeutics, Inc.
- Sold, on record
- $2.3M
- Dollars the filings state
- Form 4 sales
- 6
- Latest Mar 18, 2024
- Form 144 notices
- 5
- Proposed sales
- Companies
- 1
- Filed as an executive or holder
Companies
- Revance Therapeutics, Inc.Officer
Sales by reason
Form 4 sales per month, last 12 months.
Timeline
- 1 Form 4 sale Revance Therapeutics, Inc.Plan not statedMar 9, 2023 2023
Sold 18,496 shares at $31.59 ($584k)
Moxie Dwight, SVP, GC & Secretary
Sold 25% of holdings ($2.3M position)55,547 shares leftFollows a Form 144Filing
- 2 Form 144 notice Revance Therapeutics, Inc.NoticeMay 12, 2023 +64 days
Filed to sell 22,000 shares ($735k)
Moxie Dwight, Officer
No 10b5-1 plan2x usual sizeFiling
- 3 Form 4 sale Revance Therapeutics, Inc.No planMay 15, 2023 +3 days
Sold 21,401 shares at $34.55 ($739k)
Moxie Dwight, SVP, GC & Secretary
No 10b5-1 planSold 23.6% of holdings ($3.1M position)69,165 shares left1.9x usual sizeFollows a Form 144Filing
- 4 Form 144 notice Revance Therapeutics, Inc.NoticeSep 5, 2023 +113 days
Filed to sell 23,853 shares ($425k)
Moxie Dwight, Officer
10b5-1 plan1.6x usual sizeFiling
- 5 Form 144 notice Revance Therapeutics, Inc.NoticeSep 6, 2023 +1 day
Filed to sell 11,000 shares ($188k)
Moxie Dwight, Officer
10b5-1 plan0.7x usual sizeFiling
- 6 Form 4 sale Revance Therapeutics, Inc.RoutineSep 6, 2023 same day
Sold 34,853 shares at $17.57 ($612k)
Moxie Dwight, SVP, GC & Secretary
10b5-1 planSold 44.2% of holdings ($1.4M position)44,066 shares left2.4x usual sizeFollows a Form 144Filing
- 7 Form 144 notice Revance Therapeutics, Inc.NoticeMar 18, 2024 +194 days
Filed to sell 8,500 shares ($47k)
Moxie Dwight, Officer
No 10b5-1 plan0.4x usual sizeFiling
- 8 Form 4 sale Revance Therapeutics, Inc.No planMar 18, 2024 same day
Sold 8,125 shares at $5.04 ($41k)
Moxie Dwight, CLO & GC
No 10b5-1 planSold 5.6% of holdings ($736k position)137,815 shares left0.4x usual sizeFollows a Form 144Filing
Every transaction
Loading transactions…
Sales and notices (11)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Mar 18, 2024 | Mar 19, 2024 | Revance Therapeutics, Inc. | CLO & GC | Form 4 sale | 8,125 | $41k | 5.6% | No plan | SEC |
| Mar 18, 2024 | Mar 18, 2024 | Revance Therapeutics, Inc. | Officer | Form 144 notice | 8,500 | $47k | Notice | SEC | |
| Sep 6, 2023 | Sep 7, 2023 | Revance Therapeutics, Inc. | SVP, GC & Secretary | Form 4 sale | 34,853 | $612k | 44.2% | Routine | SEC |
| Sep 6, 2023 | Sep 6, 2023 | Revance Therapeutics, Inc. | Officer | Form 144 notice | 11,000 | $188k | Notice | SEC | |
| Sep 5, 2023 | Sep 5, 2023 | Revance Therapeutics, Inc. | Officer | Form 144 notice | 23,853 | $425k | Notice | SEC | |
| May 15, 2023 | May 16, 2023 | Revance Therapeutics, Inc. | SVP, GC & Secretary | Form 4 sale | 21,401 | $739k | 23.6% | No plan | SEC |
| May 12, 2023 | May 12, 2023 | Revance Therapeutics, Inc. | Officer | Form 144 notice | 22,000 | $735k | Notice | SEC | |
| Mar 9, 2023 | Mar 9, 2023 | Revance Therapeutics, Inc. | SVP, GC & Secretary | Form 4 sale | 18,496 | $584k | 25.0% | Plan not stated | SEC |
| Mar 8, 2023 | Mar 8, 2023 | Revance Therapeutics, Inc. | Officer | Form 144 notice | 20,000 | $660k | Notice | SEC | |
| Sep 14, 2022 | Sep 16, 2022 | Revance Therapeutics, Inc. | SVP, GC & Secretary | Form 4 sale | 11,000 | $298k | 25.8% | Unusual | SEC |
| Sep 27, 2021 | Sep 28, 2021 | Revance Therapeutics, Inc. | SVP, GC & Secretary | Form 4 sale | 1,675 | $50k | 3.4% | Plan not stated | SEC |